Elutia Inc. Q4 2025 Earnings Call Summary

Management is transitioning the company to focus exclusively on drug-eluting biologics, specifically targeting the high infection rates in breast reconstruction surgery. Performance attribution for the quarter was driven by a return to direct distribution for cardiovascular and SimpliDerm lines, improving adjusted gross margins to 66.8%. The strategic rationale for the NXT 41X platform is based on addressing a 15% to 20% postoperative infection rate that current systemic antibiotics fail to reach due ...